NCI/ADR-RES
NCI/ADR-RES is a cell line derived from the human ovarian cancer cell line OVCAR-8. It is a multi-drug resistant cell line, which is often used in biomedical research to study drug resistance mechanisms and to test new chemotherapeutic agents.
History[edit | edit source]
The NCI/ADR-RES cell line was developed by the National Cancer Institute (NCI) as part of their efforts to understand and overcome drug resistance in cancer. It was derived from the OVCAR-8 cell line, which was originally isolated from a patient with ovarian cancer. The NCI/ADR-RES cell line was selected for its resistance to adriamycin, a commonly used chemotherapeutic agent.
Characteristics[edit | edit source]
NCI/ADR-RES cells are characterized by their resistance to multiple chemotherapeutic agents, including adriamycin, vincristine, and vinblastine. This resistance is thought to be due to the overexpression of P-glycoprotein, a protein that pumps drugs out of cells, thereby reducing their effectiveness.
In addition to their drug resistance, NCI/ADR-RES cells also exhibit other characteristics that make them a useful model for studying ovarian cancer. For example, they have a high rate of cell proliferation, which mimics the rapid growth of cancer cells in the body. They also have the ability to form tumors when injected into immunocompromised mice, which allows researchers to study the growth and spread of ovarian cancer in a living organism.
Use in Research[edit | edit source]
NCI/ADR-RES cells are widely used in biomedical research. They are often used to study the mechanisms of drug resistance in cancer, and to test the effectiveness of new chemotherapeutic agents. In addition, they are used to study the biology of ovarian cancer, including the genes and pathways that are involved in its growth and spread.
See Also[edit | edit source]
References[edit | edit source]
This cell line related article is a stub. You can help WikiMD by expanding it.
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
